CA2185794C - Medicaments destines a soulager les effets secondaires provoques par des immunodepresseurs - Google Patents

Medicaments destines a soulager les effets secondaires provoques par des immunodepresseurs Download PDF

Info

Publication number
CA2185794C
CA2185794C CA002185794A CA2185794A CA2185794C CA 2185794 C CA2185794 C CA 2185794C CA 002185794 A CA002185794 A CA 002185794A CA 2185794 A CA2185794 A CA 2185794A CA 2185794 C CA2185794 C CA 2185794C
Authority
CA
Canada
Prior art keywords
hgf
side effects
immunosuppressants
relieving
effects caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002185794A
Other languages
English (en)
Other versions
CA2185794A1 (fr
Inventor
Toshikazu Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2185794A1 publication Critical patent/CA2185794A1/fr
Application granted granted Critical
Publication of CA2185794C publication Critical patent/CA2185794C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un médicament contenant un facteur de croissance des hépatocytes (HGF), utilisé comme ingrédient actif pour soulager les effets secondaires provoqués par des immunodépresseurs, un procédé de soulagement d'effets secondaires provoqués par des immunodépresseurs par administration de HGF, ainsi que l'utilisation de ce dernier dans la production du médicament. Etant donné que le HGF est utilisé pour soulager des effets secondaires sur plusieurs organes ou sur l'organisme, ce médicament peut influer sur les limitations apportées aux schémas posologiques d'immunodépresseurs, il peut améliorer à la fois la vitesse de cicatrisation dans diverses maladies et le pourcentage de succès de transplantations d'organes dans lesquelles on utilise des immunodépresseurs, et il est remarquable dans son effet de soulagement des patients.
CA002185794A 1994-03-18 1995-03-01 Medicaments destines a soulager les effets secondaires provoques par des immunodepresseurs Expired - Fee Related CA2185794C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP74272/1994 1994-03-18
JP07427294A JP3962097B2 (ja) 1994-03-18 1994-03-18 免疫抑制剤による副作用の軽減剤
PCT/JP1995/000329 WO1995025537A1 (fr) 1994-03-18 1995-03-01 Medicaments destines a soulager les effets secondaires provoques par des immunodepresseurs

Publications (2)

Publication Number Publication Date
CA2185794A1 CA2185794A1 (fr) 1995-09-28
CA2185794C true CA2185794C (fr) 2007-01-30

Family

ID=13542322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185794A Expired - Fee Related CA2185794C (fr) 1994-03-18 1995-03-01 Medicaments destines a soulager les effets secondaires provoques par des immunodepresseurs

Country Status (8)

Country Link
US (1) US5776464A (fr)
EP (1) EP0803256B1 (fr)
JP (1) JP3962097B2 (fr)
AT (1) ATE243527T1 (fr)
AU (1) AU1860895A (fr)
CA (1) CA2185794C (fr)
DE (1) DE69531166T2 (fr)
WO (1) WO1995025537A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) * 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
EP1320384B1 (fr) * 2000-08-28 2007-10-10 Damavand Wound AB Effets synergiques du facteur de croissance des hepatocytes et traitement antibacterien
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US7696170B2 (en) 2005-01-24 2010-04-13 Kringle Pharma Inc. Fibrosis inhibitor for implanted organ
US8575099B2 (en) * 2006-04-20 2013-11-05 Osaka University Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
JP2015000001A (ja) * 2013-06-12 2015-01-05 株式会社明治 過敏性腸症候群モデル動物の作成方法
CA2999511C (fr) 2015-09-11 2024-01-23 The Schepens Eye Research Institute, Inc. Compositions et methodes pour prevenir et traiter l'opacite et la cicatrisation corneennes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03204899A (ja) * 1989-09-21 1991-09-06 Otsuka Pharmaceut Co Ltd ヒト肝再生因子、そのｄｎａ塩基配列、該配列を含むプラスミド及び形質転換体並びにリコンビナント肝再生因子
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
JP3030386B2 (ja) * 1991-05-15 2000-04-10 敏一 中村 抗ガン剤
JP3394982B2 (ja) * 1991-11-07 2003-04-07 敏一 中村 ガン療法用副作用防止剤
CA2144081C (fr) * 1992-09-16 2004-11-30 Filip Roos Protection contre les lesions du foie au moyen du hgf

Also Published As

Publication number Publication date
WO1995025537A1 (fr) 1995-09-28
US5776464A (en) 1998-07-07
JP3962097B2 (ja) 2007-08-22
ATE243527T1 (de) 2003-07-15
JPH07258111A (ja) 1995-10-09
DE69531166T2 (de) 2004-05-06
DE69531166D1 (de) 2003-07-31
AU1860895A (en) 1995-10-09
CA2185794A1 (fr) 1995-09-28
EP0803256A1 (fr) 1997-10-29
EP0803256A4 (fr) 2000-07-05
EP0803256B1 (fr) 2003-06-25

Similar Documents

Publication Publication Date Title
US5130141A (en) Compositions for and methods of treating muscle degeneration and weakness
US12514821B2 (en) Pharmaceutical TACI-Fc fusion protein formulation
FR2576792A1 (fr) Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de l'arthrite rhumatoide
EP0953354A1 (fr) Agents de proliferation des cellules souches hematopoietiques
JP2010100664A (ja) 急性腎不全治療用ｈｇｆ
CA2185794C (fr) Medicaments destines a soulager les effets secondaires provoques par des immunodepresseurs
EP3881856B1 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
KR19990066997A (ko) 조혈성 간세포의 이동 방법
JP4463885B2 (ja) 劇症肝炎疾患治療剤
JPH0640938A (ja) Ｈｇｆ含有製剤
AU2004200074B2 (en) Agent for relieving side effects caused by immunosuppressants
US5534251A (en) Stabilized il-1α medicinal composition
US5849282A (en) Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
US5998370A (en) Agents for the prevention and/or treatment of radiation-induced disorders by administrating TCF-II
KR102945666B1 (ko) 인플릭시맵 및 히알루로니다제를 포함하는 피하투여용 약제학적 제제
JPH10194986A (ja) 移植肝機能改善・再生促進剤
BR112013005697B1 (pt) Formulação aquosa estável
EP0981359B1 (fr) Compositions stimulant l'activite pharmacologique des immunosuppresseurs
JP4114979B2 (ja) 拡張型心筋症治療剤
KR20260047537A (ko) 인플릭시맵 및 히알루로니다제를 포함하는 피하투여용 약제학적 제제
EP0482213A1 (fr) Agent antineoplastie
HK40059370A (en) Pharmaceutical composition for treating aplastic anemia
JPH11292790A (ja) 腎疾患治療剤
JP2007277268A (ja) 劇症肝炎疾患治療剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140303